Share on StockTwits

Auspex Pharmaceuticals (NASDAQ:ASPX) major shareholder Ventures Vii Lp Cmea unloaded 6,300 shares of the stock in a transaction that occurred on Tuesday, August 26th. The stock was sold at an average price of $21.35, for a total value of $134,505.00. Following the transaction, the insider now directly owns 3,759,872 shares of the company’s stock, valued at approximately $80,273,267. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Several analysts have recently commented on the stock. Analysts at Stifel Nicolaus raised their price target on shares of Auspex Pharmaceuticals from $39.00 to $40.00 in a research note on Friday, August 8th. They now have a “buy” rating on the stock. Analysts at Robert W. Baird raised their price target on shares of Auspex Pharmaceuticals from $34.00 to $42.00 in a research note on Friday, July 11th. They now have an “outperform” rating on the stock.

Shares of Auspex Pharmaceuticals (NASDAQ:ASPX) traded down 0.49% during mid-day trading on Thursday, hitting $22.23. The stock had a trading volume of 124,019 shares. Auspex Pharmaceuticals has a 52-week low of $13.25 and a 52-week high of $35.78. The stock has a 50-day moving average of $19.90 and a 200-day moving average of $22.9. The company’s market cap is $510.0 million.

Auspex Pharmaceuticals (NASDAQ:ASPX) last released its earnings data on Thursday, August 7th. The company reported ($0.45) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.33) by $0.12. On average, analysts predict that Auspex Pharmaceuticals will post $-2.03 earnings per share for the current fiscal year.

Auspex Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of medicines for the treatment of orphan diseases.

Receive News & Ratings for Auspex Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auspex Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.